(Q37885450)

24 August 2017

0 references

1 reference

title

Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis (English)

1 reference

24 August 2017

0 references

0 references

1 reference

A E Pontiroli

1

1 reference

24 August 2017

L Miele

series ordinal

2

1 reference

24 August 2017

A Morabito

series ordinal

3

1 reference

24 August 2017

publication date

1 November 2011

1 reference

Diabetes, Obesity and Metabolism

24 August 2017

published in

1 reference

24 August 2017

volume

13

1 reference

24 August 2017

issue

11

1 reference

24 August 2017

page(s)

1008-1019

1 reference

Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Long-term benefits of insulin therapy and glycemic control in overweight and obese adults with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Comparison of Basal and Prandial Insulin Therapy in Patients with Secondary Failure of Sulphonylurea Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Comparison of Bedtime NPH or Preprandial Regular Insulin Combined With Glibenclamide in Secondary Sulfonylurea Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Comparison of lunch and bedtime NPH insulin plus mealtime insulin Lispro therapy with premeal regular insulin plus bedtime NPH insulin therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Combined bedtime insulin--daytime sulphonylurea regimen compared with two different daily insulin regimens in type 2 diabetes: effects on HbA1c and hypoglycaemia rate--a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

A randomised trial of insulin on well-being and carer strain in elderly type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Continuing metformin when starting insulin in patients with Type 2 diabetes: a double-blind randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Basal insulin or premix analogue therapy in type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Evaluation of the superiority of insulin glargine as basal insulin replacement by continuous glucose monitoring system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Six-month multicentric, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Effect of two starting insulin regimens in patients with type II diabetes not controlled on a combination of oral antihyperglycemic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Initiating insulin therapy in elderly patients with Type 2 diabetes: efficacy and safety of lispro mix 25 vs. basal insulin combined with oral glucose-lowering agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Glycemic control with preprandial versus basal insulin in patients with type 2 diabetes mellitus poorly controlled by oral antidiabetes agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Combination therapies with insulin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Three-year efficacy of complex insulin regimens in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Evidence-based insulin treatment in type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01433.X

10.1111/J.1463-1326.2011.01433.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference